1. SIOP

    Comments Leave a Comment

    1-15 of 23 1 2 »
    1. Mentioned In 23 Articles

    2. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

      ...air T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN) Abstract BACKGROUND: High-dose chemotherapy with haemopoie...
      Read Full Article
      Mentions: SIOPEN MYCN SIOP
    3. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings - Parikh - 2015 - Pediatric Blood & Cancer

      ..., Khattab, M., Alcasabas, P., Lam, C. G., Faulkner, L., Park, J. R., London, W. B. and Matthay, K. K. (2015), SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and ...
      Read Full Article
    4. Data Presented at the International Society of Paediatric Oncology (SIOP) Congress Show Palonosetron is a Valuable Option for Treating Pediatric Patients Receiving Moderately to Highly Emetogenic Chemotherapy

      Data Presented at the International Society of Paediatric Oncology (SIOP) Congress Show Palonosetron is a Valuable Option for Treating Pediatric Patients Receiving Moderately to Highly Emetogenic Chemotherapy
      ...y controlled, can lead to dehydration, electrolyte imbalance and hospitalization. The data (presented at the SIOP congress in , 22-24 October, today, rd) derive from a large randomized trial and establish that the inv...
      Read Full Article
      Mentions: SIOP
    5. SIOP 2010 ~ Antiangiogenesis and targeting survivin

      Rakesh Jain, Raghu Kalluri, and Marsha Moses talked about angiogenesis and why metastases are promoted when giving antiangiogenetic agents. The agents create hypoxia in the tumor and an interesting series of experiments they performed support the theory that hypoxia drives metastases. Candidate biomarkers have been proposed SDF1-alpha and receptor CXCR4 to help determine which patients may benefit from antiangiogenetic agents and who should not get these agents.
      Read Full Article
      Mentions: SIOP
    6. 1-15 of 23 1 2 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video